Proof of efficacy for Seladelpar, a selective PPAR-δ agonist, in patients with primary biliary cholangitis non-responsive to ursodeoxycholic acid: results of an international Phase 2 randomised controlled clinical study
Gideon M. Hirschfield(University Health Network), DE Jones, Charles A. McWherter(University Health Network), Alexandra Steinberg(CymaBay Therapeutics (United States)), Pol Boudes(CymaBay Therapeutics (United States)), Michal Galamboš, Mark G. Swain(University of Calgary), Yu-Seong Choi, R.L. Martin, Yvonne Döerffel(Charité - Universitätsmedizin Berlin), Harinder Chera(CymaBay Therapeutics (United States)), M. Varga, Christopher L. Bowlus(University of California, Davis)
Cited by 1
Related Papers
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
|Gastroenterology|2014|563